| Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. N Bhala, J Emberson, A Merhi, S Abramson, N Arber, JA Baron, ... Lancet (London, England) 382 (9894), 769-779, 2013 | 1697 | 2013 |
| COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study LYW Lee, JB Cazier, V Angelis, R Arnold, V Bisht, NA Campton, ... The Lancet 395 (10241), 1919-1926, 2020 | 1271 | 2020 |
| Duration of adjuvant chemotherapy for stage III colon cancer A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ... New England Journal of Medicine 378 (13), 1177-1188, 2018 | 1042 | 2018 |
| Genetic prognostic and predictive markers in colorectal cancer A Walther, E Johnstone, C Swanton, R Midgley, I Tomlinson, D Kerr Nature Reviews Cancer 9 (7), 489-499, 2009 | 980 | 2009 |
| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The Lancet Oncology 21 (10), 1309-1316, 2020 | 666 | 2020 |
| A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma DH Palmer, RS Midgley, N Mirza, EE Torr, F Ahmed, JC Steele, ... Hepatology 49 (1), 124-132, 2009 | 652 | 2009 |
| Deep learning for prediction of colorectal cancer outcome: a discovery and validation study OJ Skrede, S De Raedt, A Kleppe, TS Hveem, K Liestøl, J Maddison, ... The Lancet 395 (10221), 350-360, 2020 | 531 | 2020 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 508 | 2019 |
| Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26. 2, 12q13. 13 and 20q13. 33 RS Houlston, J Cheadle, SE Dobbins, A Tenesa, AM Jones, K Howarth, ... Nature genetics 42 (11), 973-977, 2010 | 431 | 2010 |
| Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial SJ Dutton, DR Ferry, JM Blazeby, H Abbas, A Dahle-Smith, W Mansoor, ... The lancet oncology 15 (8), 894-904, 2014 | 344 | 2014 |
| The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial A Huijbers, R Tollenaar, GW v Pelt, ECM Zeestraten, S Dutton, ... Annals of oncology 24 (1), 179-185, 2013 | 334 | 2013 |
| Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ... The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016 | 331 | 2016 |
| Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk MG Dunlop, SE Dobbins, SM Farrington, AM Jones, C Palles, N Whiffin, ... Nature genetics 44 (7), 770-776, 2012 | 286 | 2012 |
| Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ... Journal of Clinical Oncology 32 (10), 1031-1039, 2014 | 280 | 2014 |
| KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer J Tie, L Lipton, J Desai, P Gibbs, RN Jorissen, M Christie, KJ Drummond, ... Clinical Cancer Research 17 (5), 1122-1130, 2011 | 269 | 2011 |
| Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer E Domingo, DN Church, O Sieber, R Ramamoorthy, Y Yanagisawa, ... Journal of clinical oncology 31 (34), 4297-4305, 2013 | 248 | 2013 |
| Association analyses identify 31 new risk loci for colorectal cancer susceptibility PJ Law, M Timofeeva, C Fernandez-Rozadilla, P Broderick, J Studd, ... Nature communications 10 (1), 2154, 2019 | 237 | 2019 |
| 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial TJ Iveson, RS Kerr, MP Saunders, J Cassidy, NH Hollander, J Tabernero, ... The Lancet Oncology 19 (4), 562-578, 2018 | 208 | 2018 |
| Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer DJ Kerr, JA Dunn, MJ Langman, JL Smith, RSJ Midgley, A Stanley, ... New England Journal of Medicine 357 (4), 360-369, 2007 | 175 | 2007 |
| Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial RS Kerr, S Love, E Segelov, E Johnstone, B Falcon, P Hewett, A Weaver, ... The Lancet Oncology 17 (11), 1543-1557, 2016 | 168 | 2016 |
